Amgen Inc. (NASDAQ:AMGN) Shares Sold by Foster Group Inc.

Foster Group Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 10.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,163 shares of the medical research company’s stock after selling 136 shares during the period. Foster Group Inc.’s holdings in Amgen were worth $258,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in AMGN. Tanglewood Legacy Advisors LLC purchased a new position in shares of Amgen in the 4th quarter valued at approximately $26,000. Ruedi Wealth Management Inc. purchased a new stake in shares of Amgen in the fourth quarter valued at approximately $27,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Amgen in the first quarter valued at approximately $28,000. GW&K Investment Management LLC boosted its stake in shares of Amgen by 200.0% in the fourth quarter. GW&K Investment Management LLC now owns 120 shares of the medical research company’s stock valued at $32,000 after buying an additional 80 shares in the last quarter. Finally, AXS Investments LLC purchased a new stake in shares of Amgen in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 74.44% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of analyst reports. Mizuho lifted their price target on Amgen from $214.00 to $223.00 and gave the company a “neutral” rating in a research note on Monday, August 14th. Truist Financial reiterated a “hold” rating and set a $260.00 target price on shares of Amgen in a research report on Tuesday, September 5th. Royal Bank of Canada boosted their target price on Amgen from $250.00 to $253.00 and gave the stock a “sector perform” rating in a research report on Friday, August 4th. HSBC assumed coverage on Amgen in a research report on Wednesday, September 6th. They set a “buy” rating and a $320.00 target price on the stock. Finally, Argus decreased their target price on Amgen from $270.00 to $260.00 in a research report on Monday, June 26th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $264.19.

Check Out Our Latest Stock Report on AMGN

Insider Activity at Amgen

In related news, EVP Murdo Gordon sold 9,558 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $262.43, for a total value of $2,508,305.94. Following the completion of the transaction, the executive vice president now directly owns 44,308 shares in the company, valued at $11,627,748.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN opened at $260.72 on Friday. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $296.67. The stock has a market cap of $139.46 billion, a price-to-earnings ratio of 17.58, a price-to-earnings-growth ratio of 3.23 and a beta of 0.61. The business has a fifty day moving average of $248.12 and a 200-day moving average of $237.71. The company has a quick ratio of 2.48, a current ratio of 2.77 and a debt-to-equity ratio of 8.76.

Amgen (NASDAQ:AMGNGet Free Report) last released its earnings results on Thursday, August 3rd. The medical research company reported $5.00 EPS for the quarter, beating the consensus estimate of $4.44 by $0.56. The firm had revenue of $7 billion during the quarter, compared to analyst estimates of $6.66 billion. Amgen had a return on equity of 196.60% and a net margin of 30.02%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.65 earnings per share. As a group, analysts predict that Amgen Inc. will post 18.35 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Friday, August 18th were paid a $2.13 dividend. The ex-dividend date of this dividend was Thursday, August 17th. This represents a $8.52 annualized dividend and a yield of 3.27%. Amgen’s payout ratio is currently 57.45%.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Read More

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.